Kedudukan dalam Saham
#24756
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Perubahan (1 hari)
-11.11%
Perubahan (1 tahun)
-20.59%
Perdagangan Solasia Pharma K.K. (4597)
Harga 4597 dengan permodalan pasaran b
Modal pasaran bagi Solasia Pharma K.K.(4597)
Modal Pasaran: $57.00M
Sehingga August 2026, Solasia Pharma K.K. mempunyai modal pasaran sebanyak $57.00M. Ini menjadikan Solasia Pharma K.K. syarikat ke-24756th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Solasia Pharma K.K. dari 2017 hingga 2026
4597 berbanding dengan 5 teratas yang paling popular stocks
| Harga 4597 |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+9,222,689.99%
|
|
|
|
|
$4.599T
|
+8,067,923.66%
|
|
|
|
|
$4.107T
|
+7,204,622.15%
|
|
|
|
|
$3.577T
|
+6,275,948.87%
|
|
|
|
|
$2.807T
|
+4,925,127.16%
|
